Additive effect of interleukin-12 and interleukin-18 on the T-helper cell pathway of malignant pleural effusion

N. S. Yao, Y. M. Chen, R. P. Perng, J. Whang-Peng

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Interleukin-18 (IL-18) is a novel cytokine with interferon-γ (IFN-γ)-inducing activity, thus favoring the T-helper type 1 (Th-1) pathway. The present study attempts to define the role of IL-18 on the functions of lymphocytes isolated from malignant pleural effusions (EAL, effusion-associated lymphocytes). EAL from 10 patients with malignant pleural effusion were incubated with IL-2, IL-12, or IL-18 with/without a αCD3 antibody. ELISA, proliferation, and cytotoxicity assays were performed. IL-18 alone was found to have no significant effect on EAL in terms of cytokine production, lymphocyte proliferation, or cytotoxicity against tumor targets. IL-18 also had no significant additive or synergistic effect on IL-2, IL-12, or αCD3 co-cultured EAL. However, when IL-18 was used with IL-12, the highest IFN-γ/IL-10 ratio was derived, suggesting that these two cytokines had an additive effect in leading EAL from the Th-2 to the Th-1 pathway. Furthermore, 1 of 5 patients' EAL had its strongest cytolytic activity against an autologous tumor when the EAL was cultured with IL-2 plus IL-18, as compared with the other 4 patients whose EAL cytolytic activity against autologous tumor was highest when using IL-2 plus αCD3. These findings suggest that IL-18 alone did not have a significant effect on EAL, and that IL-18 did not enhance αCD3's activity on EAL. However, its additive effect with IL-12 in the Th-1 pathway and with IL-2 in its cytolytic activity against an autologous tumor deserve further studies.

Original languageEnglish
Pages (from-to)15-24
Number of pages10
JournalLung
Volume180
Issue number1
DOIs
Publication statusPublished - Dec 1 2002
Externally publishedYes

Fingerprint

Malignant Pleural Effusion
Interleukin-18
Interleukin-12
Helper-Inducer T-Lymphocytes
Lymphocytes
Interleukin-2
Cytokines
Interferons
Neoplasms
Interleukin-10

Keywords

  • Interferon-γ
  • Interleukin-12
  • Interleukin-18
  • Interleukin-2
  • Malignant effusion

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Additive effect of interleukin-12 and interleukin-18 on the T-helper cell pathway of malignant pleural effusion. / Yao, N. S.; Chen, Y. M.; Perng, R. P.; Whang-Peng, J.

In: Lung, Vol. 180, No. 1, 01.12.2002, p. 15-24.

Research output: Contribution to journalArticle

@article{70c1cdc465084d358bd63f9373191050,
title = "Additive effect of interleukin-12 and interleukin-18 on the T-helper cell pathway of malignant pleural effusion",
abstract = "Interleukin-18 (IL-18) is a novel cytokine with interferon-γ (IFN-γ)-inducing activity, thus favoring the T-helper type 1 (Th-1) pathway. The present study attempts to define the role of IL-18 on the functions of lymphocytes isolated from malignant pleural effusions (EAL, effusion-associated lymphocytes). EAL from 10 patients with malignant pleural effusion were incubated with IL-2, IL-12, or IL-18 with/without a αCD3 antibody. ELISA, proliferation, and cytotoxicity assays were performed. IL-18 alone was found to have no significant effect on EAL in terms of cytokine production, lymphocyte proliferation, or cytotoxicity against tumor targets. IL-18 also had no significant additive or synergistic effect on IL-2, IL-12, or αCD3 co-cultured EAL. However, when IL-18 was used with IL-12, the highest IFN-γ/IL-10 ratio was derived, suggesting that these two cytokines had an additive effect in leading EAL from the Th-2 to the Th-1 pathway. Furthermore, 1 of 5 patients' EAL had its strongest cytolytic activity against an autologous tumor when the EAL was cultured with IL-2 plus IL-18, as compared with the other 4 patients whose EAL cytolytic activity against autologous tumor was highest when using IL-2 plus αCD3. These findings suggest that IL-18 alone did not have a significant effect on EAL, and that IL-18 did not enhance αCD3's activity on EAL. However, its additive effect with IL-12 in the Th-1 pathway and with IL-2 in its cytolytic activity against an autologous tumor deserve further studies.",
keywords = "Interferon-γ, Interleukin-12, Interleukin-18, Interleukin-2, Malignant effusion",
author = "Yao, {N. S.} and Chen, {Y. M.} and Perng, {R. P.} and J. Whang-Peng",
year = "2002",
month = "12",
day = "1",
doi = "10.1007/s004080000077",
language = "English",
volume = "180",
pages = "15--24",
journal = "Lung",
issn = "0341-2040",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Additive effect of interleukin-12 and interleukin-18 on the T-helper cell pathway of malignant pleural effusion

AU - Yao, N. S.

AU - Chen, Y. M.

AU - Perng, R. P.

AU - Whang-Peng, J.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Interleukin-18 (IL-18) is a novel cytokine with interferon-γ (IFN-γ)-inducing activity, thus favoring the T-helper type 1 (Th-1) pathway. The present study attempts to define the role of IL-18 on the functions of lymphocytes isolated from malignant pleural effusions (EAL, effusion-associated lymphocytes). EAL from 10 patients with malignant pleural effusion were incubated with IL-2, IL-12, or IL-18 with/without a αCD3 antibody. ELISA, proliferation, and cytotoxicity assays were performed. IL-18 alone was found to have no significant effect on EAL in terms of cytokine production, lymphocyte proliferation, or cytotoxicity against tumor targets. IL-18 also had no significant additive or synergistic effect on IL-2, IL-12, or αCD3 co-cultured EAL. However, when IL-18 was used with IL-12, the highest IFN-γ/IL-10 ratio was derived, suggesting that these two cytokines had an additive effect in leading EAL from the Th-2 to the Th-1 pathway. Furthermore, 1 of 5 patients' EAL had its strongest cytolytic activity against an autologous tumor when the EAL was cultured with IL-2 plus IL-18, as compared with the other 4 patients whose EAL cytolytic activity against autologous tumor was highest when using IL-2 plus αCD3. These findings suggest that IL-18 alone did not have a significant effect on EAL, and that IL-18 did not enhance αCD3's activity on EAL. However, its additive effect with IL-12 in the Th-1 pathway and with IL-2 in its cytolytic activity against an autologous tumor deserve further studies.

AB - Interleukin-18 (IL-18) is a novel cytokine with interferon-γ (IFN-γ)-inducing activity, thus favoring the T-helper type 1 (Th-1) pathway. The present study attempts to define the role of IL-18 on the functions of lymphocytes isolated from malignant pleural effusions (EAL, effusion-associated lymphocytes). EAL from 10 patients with malignant pleural effusion were incubated with IL-2, IL-12, or IL-18 with/without a αCD3 antibody. ELISA, proliferation, and cytotoxicity assays were performed. IL-18 alone was found to have no significant effect on EAL in terms of cytokine production, lymphocyte proliferation, or cytotoxicity against tumor targets. IL-18 also had no significant additive or synergistic effect on IL-2, IL-12, or αCD3 co-cultured EAL. However, when IL-18 was used with IL-12, the highest IFN-γ/IL-10 ratio was derived, suggesting that these two cytokines had an additive effect in leading EAL from the Th-2 to the Th-1 pathway. Furthermore, 1 of 5 patients' EAL had its strongest cytolytic activity against an autologous tumor when the EAL was cultured with IL-2 plus IL-18, as compared with the other 4 patients whose EAL cytolytic activity against autologous tumor was highest when using IL-2 plus αCD3. These findings suggest that IL-18 alone did not have a significant effect on EAL, and that IL-18 did not enhance αCD3's activity on EAL. However, its additive effect with IL-12 in the Th-1 pathway and with IL-2 in its cytolytic activity against an autologous tumor deserve further studies.

KW - Interferon-γ

KW - Interleukin-12

KW - Interleukin-18

KW - Interleukin-2

KW - Malignant effusion

UR - http://www.scopus.com/inward/record.url?scp=0036901999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036901999&partnerID=8YFLogxK

U2 - 10.1007/s004080000077

DO - 10.1007/s004080000077

M3 - Article

VL - 180

SP - 15

EP - 24

JO - Lung

JF - Lung

SN - 0341-2040

IS - 1

ER -